Everest Medicines Announces 2030 Strategy and Increase in Shareholdings by Directors and Substantial Shareholder

Everest Medicines Announces 2030 Strategy and Increase in Shareholdings by Directors and Substantial Shareholder

SHANGHAI, Dec. 15, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development,...

Everest Medicines Unveils 2030 Strategy as Directors and Substantial Shareholder Buy Over HKD 38 Million of Shares

HONG KONG, December 15, 2025 - (ACN Newswire) - Everest Medicines (HKEX: 1952.HK) today unveiled its 2030 strategy. Following the announcement, the Company's shares strengthened during the trading session and briefly reached an intraday high of HKD 48.54. By market close, the stock was trading at HKD 46.88, with the share price remaining at relatively elevated levels throughout the session, representing a gain of 4.55%, indicating a positive mar…